Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:Choice of first-line therapyCombinations of targeted agents and immunotherapyCombinations of immune checkpoint inhibitorsActive surveillance and monitoringCytoreductive nephrectomyPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.Link to full program: https://bit.ly/32IS9gx

There are no comments yet.

Please log in to write the first comment.